Lakewood-Amedex Biotherapeutics announced positive progress for Nu-3, a topical antimicrobial gel targeting mildly infected diabetic foot ulcers (iDFU). The company has completed key formulation and manufacturing steps under cGMP guidelines, ensuring drug stability and effectiveness for clinical use. Nu-3 belongs to the Bisphosphocin® class, which rapidly kills bacteria including resistant strains like MRSA and VRE, potentially reducing antimicrobial resistance risks. The next step is a planned Phase 2 clinical trial to evaluate safety, dosage, and treatment efficacy for iDFU patients.
In Q1 2026, Yamaha Motor Corp., USA granted over $237,000 to 13 organizations across 10 states through its Outdoor Access Initiative. These funds support trail restoration, safety upgrades, and land stewardship to enhance public land access and outdo...
The glioblastoma multiforme market is projected to grow at a 13.2% CAGR from 2026 to 2036, driven by promising late-stage therapies from companies like Avita Biomedical and Laminar Pharma. The market size was $900 million in 2025, with the US as the ...
AMD is experiencing its biggest quarterly gain since 1975, with shares up 148% driven by growing AI-related demand across CPUs, networking, and data center infrastructure. Analysts from Evercore, KeyBanc, Bernstein, Mizuho, Wells Fargo, and Bank of A...
Suntex Enterprises, through its subsidiary Red Spur Land & Ranch Co., is negotiating to acquire 100 acres in Texas for a large mixed-use development including residential and commercial projects. The development will involve multiple subsidiaries for...
Deere & Company announced a quarterly dividend of $1.62 per share, payable on August 10, 2026. The dividend will be paid to shareholders of record as of June 30, 2026. This dividend declaration reflects the company's ongoing commitment to returning v...
